Current controversies in sentinel lymph node biopsy for breast cancer

Breast

Volumn 12, Issue 3, 2003, Pages 163-171

  Allweis, Tanir M ^a   Badriyyah, M ^a   Bar Ad, V ^a   Cohen, T ^a   Freund, H R ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DYE; TRACER;

ANAPHYLAXIS; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER INVASION; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; INDIVIDUALIZATION; INJECTION SITE; INTRACUTANEOUS TEST; INTRADUCTAL CARCINOMA; LEARNING; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHOSCINTIGRAPHY; MEDICAL DECISION MAKING; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; SKIN MANIFESTATION; VALIDATION PROCESS;

EID: 0037603472     PISSN: 09609776     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-9776(03)00024-9     Document Type: Review

References (60)

1. Lucci Jr A, Kelemen P R, 3rd Miller C, Chardkoff L, Wilson L. National practice patterns of sentinel lymph node dissection for breast carcinoma. J Am Coll Surg 2001; 192(4): 453-458.
2. Krag D N, Weaver D L, Alex J C, Fairbank J T. Surgical resection and radiolocalization of the sentinel lymph node in breast cancer using a gamma probe. Surg Oncol 1993; 2(6): 335-339; discussion 340.
3. Giuliano A E, Kirgan D M, Guenther J M, Morton D L. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994; 220(3): 391-398; discussion 398-401.
4. Albertini J J, Lyman G H, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276(22): 1818-1822.
5. Schrenk P, Rieger R, Shamiyeh A, Wayand W. Morbidity following sentinel lymph node biopsy Versus axillary lymph node dissection for patients with breast carcinoma. Cancer 2000; 88(3): 608-614.
6. Burak W E, Hollenbeck S T, Zervos E E et al. Sentinel lymph node biopsy results in less postoperative morbidity compared with axillary lymph node dissection for breast cancer. Am J Surg 2002; 183(1): 23-27.
7. Dowlatshahi K, Fan M, Anderson J M, Bloom K J. Occult metastases in sentinel nodes of 200 patients with operable breast cancer. Ann Surg Oncol 2001; 8(8): 675-681.
8. Wong S L, Chao C, Edwards M J, Simpson D, McMasters K M. The use of cytokeratin staining in sentinel lymph node biopsy for breast cancer. Am J Surg 2001; 182(4): 330-334.
9. Schwartz G F, Giuliano A E, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer 2002; 94(10): 2542-2551.
10. Krag D, Weaver D, Ashikaga T et al. The sentinel node in breast cancer - a multicenter validation study. N Engl J Med 1998; 339(14): 941-946.
11. Cody 3rd H S, Hill A D, Tran K N, Brennan M F, Borgen P I. Credentialing for breast lymphatic mapping: how many cases are enough? Ann Surg 1999; 229(5): 723-726; discussion 726-728.
12. McMasters K M, Wong S L, Chao C et al. Defining the optimal surgeon experience for breast cancer sentinel lymph node biopsy: a model for implementation of new surgical techniques. Ann Surg 2001; 234(3): 292-299; discussion 299-300.
13. Dupont E, Cox C, Shivers S et al. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001; 97(1): 92-96.
14. Cox C E, Salud C J, Cantor A et al. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001; 193(6): 593-600.
15. Tanis P J, Deurloo E E, Valdes Olmos R A et al. Single intralesional tracer dose for radio-guided excision of clinically occult breast cancer and sentinel node. Ann Surg Oncol 2001; 8(10): 850-855.
16. Valdes-Olmos R A, Jansen L, Hoefnagel C A et al. Evaluation of mammary lymphoscintigraphy by a single intratumoral injection for sentinel node identification. J Nucl Med 2000; 41(9): 1500-1506.
17. McMasters K M, Wong S L, Martin 2nd R C et al. Dermal injection of radioactive colloid is superior to peritumoral injection for breast cancer sentinel lymph node biopsy: results of a multiinstitutional study. Ann Surg 2001; 233(5): 676-687.
18. Martin R C, Derossis A M, Fey J et al. Intradermal isotope injection is superior to intramammary in sentinel node biopsy for breast cancer. Surgery 2001; 130(3): 432-438.
19. Linehan D C, Hill A D, Akhurst T et al. Intradermal radiocolloid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999; 6(5): 450-454.
20. Kern K A. Sentinel lymph node mapping in breast cancer using subareolar injection of blue dye. J Am Coll Surg 1999; 189(6): 539-545.
21. Klimberg V S, Rubio I T, Henry R et al. Subareolar versus peritumoral injection for location of the sentinel lymph node. Ann Surg 1999; 229(6): 860-864; discussion 864-865.
22. Smith L F, Cross M J, Klimberg V S. Subareolar injection is a better technique for sentinel lymph node biopsy. Am J Surg 2000; 180(6): 434-437; discussion 437-438.
23. Bauer T W, Spitz F R, Callans L S et al. Subareolar and peritumoral injection identify similar sentinel nodes for breast cancer. Ann Surg Oncol 2002; 9(2): 169-176.
24. Shimazu K, Tamaki Y, Taguchi T, Takamura Y, Noguchi S. Comparison between periareolar and peritumoral injection of radiotracer for sentinel lymph node biopsy in patients with breast cancer. Surgery 2002; 131(3): 277-286.
25. Borgstein P J, Meijer S, Pijpers R J, van Diest P J. Functional lymphatic anatomy for sentinel node biopsy in breast cancer: echoes from the past and the periareolar blue method. Ann Surg 2000; 232(1): 81-89.
26. Uren R F, Howman-Giles R, Renwick S B, Gillett D, Lymphatic mapping of the breast: locating the sentinel lymph nodes. World J Surg 2001; 25(6): 789-793.
27. Dupont E L, Kamath V J, Ramnath E M et al. The role of lymphoscintigraphy in the management of the patient with breast cancer. Ann Surg Oncol 2001; 8(4): 354-360.
28. McMasters K M, Wong S L, Tuttle T M et al. Preoperative lymphoscintigraphy for breast cancer does not improve the ability to identify axillary sentinel lymph nodes. Ann Surg 2000; 231(5): 724-731.
29. Burak Jr. W E, Walker M J, Yee L D et al. Routine preoperative lymphoscintigraphy is not necessary prior to sentinel node biopsy for breast cancer. Am J Surg 1999; 177(6): 445-449.
30. Derossis A M, Fey J, Yeung H et al. A trend analysis of the relative value of blue dye and isotope localization in 2000 consecutive cases of sentinel node biopsy for breast cancer. J Am Coll Surg 2001; 193(5): 473-478.
31. Cox C E, Nguyen K, Gray R J et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001; 67(6): 513-519; discussion 519-521.
32. Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15(7): 2483-2493.
33. Fisher B, Bryant J, Wolmark N et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1999; 16(8): 2672-2685.
34. Mamounas E P, Fisher B. Preoperative chemotherapy for operable breast cancer. Cancer Treat Res 2000; 103: 137-155.
35. Cohen L F, Breslin T M, Kuerer H M, Ross M I, Hunt K K, Sahin A A. Identification and evaluation of axillary sentinel lymph nodes in patients with breast carcinoma treated with neoadjuvant chemotherapy. Am J Surg Pathol 2000; 24(9): 1266-1272.
36. Breslin T M, Cohen L, Sahin A et al. Sentinel lymph node biopsy is accurate after neoadjuvant chemotherapy for breast cancer. J Clin Oncol 2000; 18(20): 3480-3486.
37. Nason K S, Anderson B O, Byrd D R et al. Increased false negative sentinel node biopsy rates after preoperative chemotherapy for invasive breast carcinoma. Cancer 2000; 89(11): 2187-2194.
38. Fernandez A, Cortes M, Benito E et al. Gamma probe sentinel node localization and biopsy in breast cancer patients treated with a neoadjuvant chemotherapy scheme. Nucl Med Commun 2001; 22(4): 361-366.
39. Tafra L, Verbanac K M, Lannin D R. Preoperative chemotherapy and sentinel lymphadenectomy for breast cancer. Am J Surg 2001; 182(4): 312-315.
40. Haid A, Tausch C, Lang A et al. Is sentinel lymph node biopsy reliable and indicated after preoperative chemotherapy in patients with breast carcinoma? Cancer 2001; 92(5): 1080-1084.
41. Brady E W. Sentinel lymph node mapping following neoadjuvant chemotherapy for breast cancer. Breast J 2002; 8(2): 97-100.
42. Stearns V, Ewing C A, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9(3): 235-242.
43. Miller A R, Thomason V E, Yeh I T et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 2002; 9(3): 243-247.
44. Julian T B, Dusi D, Wolmark N. Sentinel node biopsy after neoadjuvant chemotherapy for breast cancer. Am J Surg 2002; 184(4): 315-317.
45. Veronesi U, Cascinelli N, Bufalino R et al. Risk of internal mammary lymph node metastases and its relevance on prognosis of breast cancer patients. Ann Surg 1983; 198(6): 681-684.
46. Johnson N, Soot L, Nelson J et al. Sentinel node biopsy and internal mammary lymphatic mapping in breast cancer. Am J Surg 2000; 179(5): 386-388.
47. Dupont E L, Salud C J, Peltz E S et al. Clinical relevance of internal mammary node mapping as a guide to radiation therapy. Am J Surg 2001; 182(4): 321-324.
48. Jansen L, Doting M H, Rutgers E J et al. Clinical relevance of sentinel lymph nodes outside the axilla in patients with breast cancer. Br J Surg 2000; 87(7): 920-925.
49. van der Ent F W, Kengen R A, van der Pol H A et al. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg 2001; 234(1): 79-84.
50. Noguchi M. Therapeutic relevance of breast cancer micrometastases in sentinel lymph nodes. Br J Surg 2002; 89(12): 1505-1515.
51. Singletary S E, Allred C, Ashley P et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002; 20(17): 3628-3636.
52. Cote R J, Peterson H F, Chaiwun B et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354(9182): 896-900.
53. Hainsworth P J, Tjandra J J, Stillwell R G et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg 1993; 80(4): 459-463.
54. McGuckin M A, Cummings M C, Walsh M D et al. Occult axillary node metastases in breast cancer: their detection and prognostic significance. Br J Cancer 1996; 73(1): 88-95.
55. Millis R R, Springall R, Lee A H et al. Occult axillary lymph node metastases are of no prognostic significance in breast cancer. Br J Cancer 2002; 86(3): 396-401.
56. Nasser I A, Lee A K, Bosari S et al. Occult axillary lymph node metastases in 'node-negative' breast carcinoma. Hum Pathol 1993; 24(9): 950-957.
57. Viale G, Maiorano E, Mazzarol G et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92(6): 1378-1384.
58. Teng S, Dupont E, McCann C et al. Do cytokeratin-positive-only sentinel lymph nodes warrant complete axillary lymph node dissection in patients with invasive breast cancer? Am Surg 2000; 66(6): 574-578.
59. Giuliano A E, Haigh P I, Brennan M B et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol 2000; 18(13): 2553-2559.
60. Chung M A, Steinhoff M M, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 2002; 184(4): 310-314.